Directory
Antonia Salud Salvia

Antonia Salud Salvia

Degree: PhD


masalud.lleida.ics(ELIMINAR)@gencat.cat

Groups

Publications

  • Rodriguez, JV; Piñol, M; Sorolla, MA; Parisi, E; Sorolla, A; Santacana, M; Ruiz, M; Parra, G; Bernabeu, M; Iglesias, M; Aracil, C; Escartin, A; VILARDELL, F; Matias-Guiu, X; Salud, A; Montal, R

    Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies

    Journal for ImmunoTherapy of Cancer 13 -. .

    [doi:10.1136/jitc-2024-010024]

  • Xu, CM; Mannucci, A; Esposito, F; Oliveres, H; Alonso-Orduña, V; Yubero, A; Fernández-Martos, C; Salud, A; Gallego, J; Martín-Richard, M; Fernández-Plana, J; Guillot, M; Aparicio, J; Fakih, M; Kopetz, S; Feliu, J; Maurel, J; Goel, A

    An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study

    CLINICAL CANCER RESEARCH 31 1002-1015. .

    [doi:10.1158/1078-0432.CCR-24-1934]

  • García-Alfonso, P; Elez, E; Soto-Alsar, J; Páez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Gómez-España, MA; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; Grávalos, C; González-Flores, E; Guix, M; Paredes, BG; Reina, JJ; Mowbray, JRR; Sastre, J; Aranda, E

    Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

    ESMO Open 9 103986-103986. .

    [doi:10.1016/j.esmoop.2024.103986]

  • Hidalgo, I; Sorolla, MA; Sorolla, A; Salud, A; Parisi, E

    Secreted Phospholipases A2: Drivers of Inflammation and Cancer

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 25 -. .

    [doi:10.3390/ijms252212408]

  • Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R

    Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis (vol 201, 104416, 2024)

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 202 104466-104466. .

    [doi:10.1016/j.critrevonc.2024.104466]

  • Rodríguez, JV; Prieto, A; Vilaprinyo, E; Bonet, M; Diez, M; Salud, A; Montal, R

    Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis

    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 201 104416-104416. .

    [doi:10.1016/j.critrevonc.2024.104416]

  • Valladares-Ayerbes, M; Safont, MJ; Flores, EG; García-Alfonso, P; Aranda, E; Muñoz, AML; Ferrer, EF; Nogueras, LC; Rodríguez-Salas, N; Aparicio, J; Muñoz, ML; Cáceres, PPP; Trujillo, OAC; Tocino, RV; Fernández, MS; Salud-Salvia, A; Sureda, BM; Garcia-Carbonero, R; Conesa, MAV; Vila, AL

    Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    CLINICAL & TRANSLATIONAL ONCOLOGY 26 2640-2651. .

    [doi:10.1007/s12094-024-03487-4]

  • Marqués M; Pont M; Hidalgo I; Sorolla MA; Parisi E; Salud A; Sorolla A; Porcel JM

    MicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 -. .

    [doi:10.3390/ijms241814022]

  • Pont, M; Marques, M; Sorolla, MA; Parisi, E; Urdanibia, I; Morales, S; Salud, A; Sorolla, A

    Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research

    Cancers 15 -. .

    [doi:10.3390/cancers15174364]

  • Parisi, E; Hidalgo, I; Montal, R; Pallise, O; Tarragona, J; Sorolla, A; Novell, A; Campbell, K; Sorolla, MA; Casali, A; Salud, A

    PLA2G12A as a Novel Biomarker for Colorectal Cancer with Prognostic Relevance

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 24 -. .

    [doi:10.3390/ijms241310889]

  • Oronich, A; Pallise, O; Salud, A; Montal, R

    Genomic alterations and targeted therapies in extrahepatic cholangiocarcinoma

    Hepatoma Research 9 -. .

    [doi:10.20517/2394-5079.2023.04]

  • Valladares-Ayerbes M; Garcia-Alfonso P; Muñoz Luengo J; Pimentel Caceres PP; Castillo Trujillo OA; Vidal-Tocino R; Llanos M; Llorente Ayala B; Limon Miron ML; Salud A; Cirera Nogueras L; Garcia-Carbonero R; Safont MJ; Falco Ferrer E; Aparicio J; Vicente Conesa MA; Guillén-Ponce C; Garcia-Teijido P; Medina Magan MB; Busquier I; Salgado M; Lloansí Vila A

    Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.

    Cancers 14 -. .

    [doi:10.3390/cancers14246075]

Projects

  • Decodificación de la metástasis del cáncer colorrectal desentrañando el señalosoma de PLA2G12A
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante